The U.S. Food and Drug Administration (FDA) has approved Horizant (gabapentin enacarbil) Extended-Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome in adults. Horizant is not recommended for patients who are required to sleep during the daytime and remain awake at night. The efficacy of Horizant in the treatment of patients with moderate-to-severe primary Restless Legs Syndrome was demonstrated in two 12-week clinical trials in adults. It is the first medication in its class to be approved for the treatment of moderate-to-severe primary Restless Legs Syndrome. Horizant is also approved for the management of postherpetic neuralgia (PHN) in adults.
Horizant is an anti-seizure used to prevent epilepsy by controlling convulsions and relieving pain. It also treats Postherpetic neuralgia and restless leg syndrome. Horizant comes in different forms like sustained release, immediate release which makes it absorbed in the body in a different form
Horizant belongs to the a drug class known as an anticonvulsant or anti-seizure drugs. It is used to treat moderate to severe restless legs syndrome in adults. This medication can also be used to relieve nerve pain following shingles, which is a painful rash that is caused by herpes zoster infection.
Horizant may also be used to treat seizures and other painful nerve conditions or neuropathic pain. Do not use this drug if you want to sleep during the daytime and need to stay awake at night.
Horizant works in certain areas of the brain to reduce the symptoms of restless leg syndrome.